Kara Chew, MD
Infectious Disease · Los Angeles, CANPI 1013116557
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,182 of the $3,605 with a category attached, or 88.3%. Shionogi Inc accounts for 91.4% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $3,293, more than ten times the $250 reported in 2019.
Across 6 payments — averaging $600.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$3K
- Johnson & Johnson$250
- Viiv Healthcare Company$62
Across 12 payments — averaging $13,592 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$132K
- Amgen$26K
- Pfizer$5K
What the payments were for
- Consulting fees$2507%
- Speaking & faculty fees$3,18288%
- Food & beverage$1735%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 2 | $3,293 |
| Johnson & Johnson | 1 | $250 |
| Viiv Healthcare Company | 3 | $62 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- S-217622$3,182
How this compares
$3,605 in reported general payments places this provider in the 80th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 26 | $101,125 |
| Fluticasone Propionate | 11 | $93 |
| Atorvastatin Calcium | 16 | $26 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Los Angeles
- Jay GladsteinLos Angeles$657K
- Otto YangLos Angeles$472K
- Irving PosalskiLos Angeles$234K
- Peter RuaneLos Angeles$174K
- Raphael LandovitzLos Angeles$147K
- Jeffrey KlausnerLos Angeles$126K
- Harold Glenn San AgustinLos Angeles$82K
- Fred SattlerLos Angeles$63K
- Judith CurrierLos Angeles$32K
- David HaakeLos Angeles$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.